Medulla Communications Pvt. Ltd., one of the world's most awarded healthcare-specialist advertising agencies, has announced ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

Founded by Praful Akali in 2008, Medulla Communications has consistently been recognized as one of the top healthcare ...

The clean-up bill for Swiss pharma giant Roche’s former manufacturing site in Co Clare now totals €150.5m in what the company ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

US and Japanese stock indexes are at all-time highs as the world adapts to President Trump's trade policy, tariffs bring in ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Novartis, a New Jersey drug manufacturer, filed the lawsuit in federal court in Portland over the program that allows hospitals and community health centers to get some medications at discount prices.

Drugs to treat attention deficit hyperactivity disorder were linked to a reduced risk of suicidal behavior, substance misuse and criminality in the first research of its kind.

A 47-year-old pharmaceutical executive from New Jersey has been charged with aggravated manslaughter, vehicular homicide and assault by auto in connection with a high-speed, wrong-way crash that ...

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio ...